Indications for therapeutic platelet transfusions

Blood Reviews

Volumn 12, Issue 4, 1998, Pages 227-233

  Hunt, B J ^a,b,c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ALLOIMMUNIZATION; BLEEDING; BLOOD TRANSFUSION REACTION; BONE MARROW DEPRESSION; DISSEMINATED INTRAVASCULAR CLOTTING; EVIDENCE BASED MEDICINE; HUMAN; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA;

EID: 0032428725     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(98)90003-0     Document Type: Conference Paper

References (65)

1. Wallace EL, Churchill WH, Surgenor DM, Cho G, McGurk S, Murphy L. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995; 35: 802-812.
2. The Sanguis Study Group. Use of blood products for elective surgery in 43 European hospitals. Transfusion Medicine 1994; 4: 251-268.
3. Thompson A, Contreras M, Knowles S. Blood component treatment: a retrospective audit in five major London hospitals. BMJ 1991; 44: 734-737.
4. Mozes B, Epstein M, Ben-Bassat I, Modan B, Halkinh H. Evaluation of appropriateness of blood and blood product usage using present criteria. Transfusion 1989; 29: 473-476.
5. Metz J, McGrath M, Copperchini ML et al. Appropriateness of transfusion of red cells, platelets and fresh frozen plasma. Med J Aust 1995; 162: 572-577.
6. Duke WW. The relation of blood platelets to haemorrhagic disease. JAMA 1910; 60: 1185-1192.
7. British Society of Haematology SH Guidelines for platelet transfusion. Transfusion Medicine 1992; 2: 311-318.
8. NIH Consensus Conference. Platelet transfusion therapy. JAMA 1987; 257: 1777-1780.
9. Gaydos LA, Freireich EF, Mantel N. The quantitive relation between platelet count and hemorrhage in patients with acute leukaemia. N Engl J Med 1962; 266: 905-909.
10. Slichter SJ. Controversies in platelet transfusion therapy. Annual Review of Medicine 1980; 31: 509-540.
11. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. New Engl J Med 1972; 287: 155-159.
12. Hamblin T, Editorial. The bleeding time. Lancet 1991; 337: 144701448.
13. Levin RH. Handbook for platelet transfusion therapy (Special publication). Bethesda, ND, National Cancer Institute 1964.
14. Han T, Stutzman L, Cohen E et al. Effect of platelet transfusion on haemorrhage in patients with acute leukaemia. Cancer 1966; 19:1937.
15. Hersh EM, Bodey GP, Nies BA et al. Causes of death in acute leukaemia: a ten year study of 414 patients from 1954-1963. JAMA 1965; 193: 99-103.
16. Task Force of the College of the American Pathologists. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. JAMA 1994; 271: 777-781.
17. Rodgers RP, Levin IA. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16: 1-20.
18. Carr JM, Krushall MS, Kaye JA et al. Efficacy of platelet transfusion in immune thrombocytopenia. Am J Med 1986; 80: 1051-1054.
19. Shulman NR, Reid DM. Platelet immunology. In Cloman RW, Hirsh J, Marder VJ, Salzman E (Eds). Haemostasis and thrombosis: basic principles and practice. Philadelphia, JB Lippincott 1994; pp 414-468.
20. Win N, Peterkin MA, Watson WH. The therapeutic value of HPA-la-negative platelet transfusion in post-transfusion purpura complicated by life-threatening haemorrhage (Case report). Vox Sang 1995; 69: 138-39.
21. Mueller-Eckhardt C. Post-transfusion purpura. Brit J Haem 1986; 64: 419-424.
22. Mueller-Eckhardt C, Lechner K, Heinrich D et al. High-dose intravenous immunoglobulin for post-transfusion purpura. New Engl J Med 1983; 308: 287.
23. Kaplan C, Morel-Kopp, Clemenceau S, Daffos F, Forestier F, Tchernia G. Fetal and neonatal alloimmune thrombocytopenia. Transfusion Medicine 1992; 2: 265-271 (GET).
24. Lynch I, Bussel JB, McFarland JG, Chitkara U, Berkowitz RL. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynaecol 1992; 80: 67-71.
25. Murphy MF, Waters AH, Doughty HA, Hambley H, Mibashan RS. Antenatal management of fetomaternal alloimmune thrombocytopenia-report of 15 affected pregnancies. Transfusion Medicine 1994; 4: 281-292.
26. Waters A, Murphy M, Hambley H, Nicolaides K. Managment of alloimmune thrombocytopenia in the fetus and neonate. In: Nace SJ, ed. Clinical and basic science aspects of immunohaematology. American Association of Blood Banks, Arlington, VA 1991: 155-177.
27. Amiral J, Bridey F, Dreyfus M et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-96.
28. Cimo PL, Moake JL, Weinger RS, Ben-Menachem Y, Khalil KG. Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses. Am J Hematol 1979; 6: 125 (GET).
29. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced thrombocytopenia. New Eng J Med 1976; 295: 237.
30. Counts RB, Haisch C, Simon TL, Maxwell DG, Heimbach DM, Carrico CJ. Hemostasis in massively transfused trauma patients. Ann Surg 1979; 190: 91-99.
31. Noe DA, Graham SM. Luff R, Sohmer P. Platelet counts during rapid massive transfusion. Transfusion 1981; 22: 392-95.
32. Mannucci PM, Federici AB, Sirchia G. Hemostasis testing during massive blood replacement. Vox Sanguis 1982; 42: 113-123.
33. Hirsch J, Fletcher AP, Sherry S. Am J Physiol 1965; 209: 415.
34. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanisms of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-34.
35. Harker LA. Bleeding after cardiopulmonary bypass. New Engl J Med 1986; 314: 1446-7.
36. Soloway HB, Cornett BM, Donahoo JV, Cox SP. Differentiation of bleeding diathesis which occur following protamine correction of heparin anticoagulation. Am J Clin Pathol 1973; 18: 188-91.
37. Holloway DS, Summaria L, Sandesara J, Vagher JP, Alexander JC, Caprinin JA. Decreased platelet number and function and increased fibrinolysis contribute to posterative bleeding in cardiopulmonary bypass. Thromb Haemost 1988; 59: 62-7.
38. Royston D. High-dose aprotinin therapy; a review of the first five years experience. J Cardiothoracic Vascular Anaesthesia 1992; 6: 76-100.
39. Davis R, Whittingot R. Aprotinin Drugs 1996; 49: 954-983.
40. Horrow JC, Hlavecek J, Strong MD. Prophylactic tranexamic acid decreased bleeding after cardiac operations. J Thorac Cardiovasc Surg 1990; 99: 70-74.
41. Hunt BJ, Segal H. Hyperfibrinolysis. J Clin Pathol 1996; 49: 958.
42. Bracey AW, Radovancevic R, Radovancevic B, McAllister HA, Vaughn WK, Cooley DA. Blood use in patients undergoing repeat coronary artery bypass graft procedures: multivariate analysis. Transfusion 1995; 35: 850-854.
43. Taggart DP, Siddiqui A, Wheatley DJ. Low-dose, preoperative aspirin therapy, postoperative blood loss, and transfusion requirements. Ann Thorac Surg 1990; 50: 425-8.
44. Triulzi DJ, Gilmor GD, Ness PM, Baumgartner WA, Schultheis. Efficacy of autologous fresh whole blood or platelet-rich plasma in adult cardiac surgery. Transfusion 1995; 35: 627-634.
45. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108: 1083-1091.
46. Hunt BJ. Desmopressin and bleeding during invasive surgery. Europ J Anaesthesiology 1997; 14(suppl 14): 2-49.
47. Burns ER, Billett HH, Fraser RWM, Sisto DA. The preoperative bleeding time as a predictor of postoperative haemorrhage after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1986; 92: 310-312.
48. Simon TL, Akl BF, Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg 1984; 37: 359-64.
49. Gooodnough LT, Johnston MFM, Ramsey G et al. Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 1990; 50: 675-83.
50. Angelini GD, Cooper GJ, Lamarra M, Bryan AJ. Unorthodox use of aprotinin to control life-threatening bleeding after cardiopulmonary bypass. Lancet 1990; 335: 799-800.
51. Kallis P, Tooze JA, Talbot S, Cowans D, Bevan DH, Treasure T. Aprotinin inhibits fibrinolysis, improves platelet adhesion and reduced blood loss. Eur J Cardiothorac Surg 1994; 8: 315-323.
52. Segal H, Hunt BJ, Cottam S et al. Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin. Transplantation 1994; 58: 1356-1360.
53. Mallett, S.V. and Cox, D.J.A. Thrombelastography. Br J Anaesth 1992; 69: 307-313.
54. Baglin T. Disseminated intravascular coagulation. BMJ.
55. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease Blood 1990; 75: 1383-1395.
56. Castillo R, Monteagudo J, Escolar G, Ordinas A, Magallom, Villar JM. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood 1991; 77: 1901-1905.
57. Laursen B, Jacobsen SEH, Taaning E et al. Transfusion problems in patients with Glanzmann's thrombasthenia. Eur J Haematol 1992; 49: 143-4.
58. Eberst ME, Berkowitz LR. Haemostasis in renal disease: pathophysiology and management. Am J Med 1994; 96: 168-179.
59. Janson PA, Jublirer SJ, Weinstein MJ et al. Treatment of the bleeding tendancy in uraemia with cryoprecipitate. N Eng J Med 1980; 303: 1318-1322.
60. Blanchette VS, Kuhne T, Hume H, Hellman J. Platelet transfusion therapy in newborm infants. Transfusion Medicine Reviews 1995; IX: 215-230.
61. Andrew M, Castle V, Mitchell L et al. Modified bleeding time in the infant. Am J Haematol 1989; 30: 190-191.
62. Andrew M, Paes B, Bowker J et al. Evaluation of an automated bleeding time device in the newborn. Am J Haematol 1990; 35: 275-77.
63. Moake JL. TTP-desperation. empiricism, progress (Editorial). N Engl J Med 1991; 325: 426-8.
64. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome - clinical experience in 108 cases. N Engl J Med 1991; 325: 398-103.
65. Lok S, Kauschansky K, Holly RD et al. Cloning and sequencing of murine thrombopoietin and stimulation of platelet production in vivo. Nature 1994; 369: 565-568.